- Home
- SLNO vs RDY Comparison
SLNO vs RDY Comparison
Compare SLNO & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- RDY
- Stock Information
- Founded
- SLNO 1999
- RDY 1984
- Country
- SLNO United States
- RDY India
- Employees
- SLNO N/A
- RDY N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- RDY Health Care
- Exchange
- SLNO Nasdaq
- RDY Nasdaq
- Market Cap
- SLNO 2.2B
- RDY 2.5B
- IPO Year
- SLNO 2014
- RDY N/A
- Fundamental
- Price
- SLNO $46.13
- RDY $13.35
- Analyst Decision
- SLNO Strong Buy
- RDY Buy
- Analyst Count
- SLNO 5
- RDY 1
- Target Price
- SLNO $71.20
- RDY $17.00
- AVG Volume (30 Days)
- SLNO 390.6K
- RDY 1.8M
- Earning Date
- SLNO 03-05-2025
- RDY 01-23-2025
- Dividend Yield
- SLNO N/A
- RDY 3.60%
- EPS Growth
- SLNO N/A
- RDY 2.68
- EPS
- SLNO N/A
- RDY 0.75
- Revenue
- SLNO N/A
- RDY $3,637,607,642.00
- Revenue This Year
- SLNO N/A
- RDY $17.23
- Revenue Next Year
- SLNO N/A
- RDY $9.20
- P/E Ratio
- SLNO N/A
- RDY $17.68
- Revenue Growth
- SLNO N/A
- RDY 14.74
- 52 Week Low
- SLNO $36.61
- RDY $13.16
- 52 Week High
- SLNO $60.92
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- SLNO 40.51
- RDY 33.41
- Support Level
- SLNO $48.48
- RDY $13.16
- Resistance Level
- SLNO $52.46
- RDY $13.46
- Average True Range (ATR)
- SLNO 2.07
- RDY 0.15
- MACD
- SLNO -0.47
- RDY -0.01
- Stochastic Oscillator
- SLNO 0.94
- RDY 21.02
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.